Menu
Menu
The pharmaceutical sector requires dynamic and rigorous collaborators who can provide solutions and support during the research and development of new active ingredients and products, as well as in the performance of studies that demonstrate their safety in the different stages of development, from pre-clinical to clinical phases.
At GAIKER, we have state-of-the-art tools and equipment that enable us to provide a wide range of tests that are adapted to customer needs for the R&D of active ingredients (APIs) and formulations (prototypes or end products).
We apply and combine various cellular and biomolecular technologies that enable us to generate biological models in the laboratory to robustly and reliably study the performance of active ingredients and drugs.
We are experts in the evaluation of toxicity and efficacy in ex vivo cell systems and tissues. We conduct customised studies of the action mechanisms of active ingredients, with physiological models that we develop ourselves, as well as studies based on conventional protocols, following international guidelines in the field of safety.
We have models of the different physiological barriers and other systems of interest, such as the skin, the digestive system, blood, the respiratory system and the central nervous system.
Since 1998, we have been carrying out ADME-Tox studies under the guarantee of Good Laboratory Practices (GLP), certified by the Ministry of Health and Social Policy.
Obtaining a line of products with effective phyto-factors (PF) for hygiene and hydration in the treatment of atopic dermatitis, which does not alter the properties of the skin or its microbiota, and does not affect the patient's immune system.
Development of new in vitro disease models and efficacy and toxicology studies of therapeutic compounds for rare diseases within the Basque Country.
Subsidised by the Basque Government
Toxicological and physicochemical evaluation of nanomaterials derived from industrial processes, based on a real case study: 3D printing.
Subsidised by the Basque Government
Launch of a cooperative networking platform to develop, characterise, optimise and test multifunctional autologous formulations rich in growth factors for use in regenerative medicine.
Subsidised by the Basque Government
Development of a new integrated model to speed up the identification and development of drug candidates for treating nervous system diseases. Reduction in the failure rate of molecules that advance during the pre-clinical and clinical development process, to enable decisions to be made early in the process and help optimise resources and achieve better, more effective medicines for this group of diseases.
No results found.
Subscribe to our newsletter
